Cargando…
Isoliquiritigenin suppresses human T Lymphocyte activation via covalently binding cysteine 46 of IκB kinase
The efficacious practice of precision personalized medicine requires a more exact understanding of the molecular mechanisms of drug, hence then it is necessary to identify the binding site of the drugs derived from natural sources. In the study, we investigated the suppressive effect and underlying...
Autores principales: | Yan, Fenggen, Yang, Fen, Wang, Rui, Yao, Xiao Jun, Bai, Liping, Zeng, Xing, Huang, JiaJun, Wong, Vincent Kam Wai, Lam, Christopher Wai Kei, Zhou, Hua, Su, Xiaohui, Liu, Juan, Li, Ting, Liu, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470962/ https://www.ncbi.nlm.nih.gov/pubmed/27626700 http://dx.doi.org/10.18632/oncotarget.11934 |
Ejemplares similares
-
Mutation of cysteine 46 in IKK-beta increases inflammatory responses
por: Li, Ting, et al.
Publicado: (2015) -
Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development
por: Huang, Fangjiao, et al.
Publicado: (2022) -
Isoliquiritigenin Attenuates Atherogenesis in Apolipoprotein E-Deficient Mice
por: Du, Fen, et al.
Publicado: (2016) -
Perspectives on the Role of Isoliquiritigenin in Cancer
por: Wang, Kai-Lee, et al.
Publicado: (2021) -
Effects of isoliquiritigenin on ovarian cancer cells
por: Li, Nan, et al.
Publicado: (2018)